Cargando…

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities

Detalles Bibliográficos
Autores principales:	Diorio, Caroline, Vatsayan, Anant, Talleur, Aimee C., Annesley, Colleen, Jaroscak, Jennifer J., Shalabi, Haneen, Ombrello, Amanda K., Hudspeth, Michelle, Maude, Shannon L., Gardner, Rebecca A., Shah, Nirali N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198909/ https://www.ncbi.nlm.nih.gov/pubmed/35395068 http://dx.doi.org/10.1182/bloodadvances.2022006983

Ejemplares similares

Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia
por: Mo, George, et al.
Publicado: (2020)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms
por: Talleur, Aimee C., et al.
Publicado: (2023)

Refractory Sweet Syndrome Treated with Anakinra
por: Shahid, Zainab, et al.
Publicado: (2019)

Immunotherapy Associated Neurotoxicity in Pediatric Oncology
por: Shalabi, Haneen, et al.
Publicado: (2022)

How I treat refractory CRS and ICANS after CAR T-cell therapy
por: Jain, Michael D., et al.
Publicado: (2023)

PW02-003 - Efficacy of anakinra in etanercept-resistant TRAPS
por: Ombrello, AK, et al.
Publicado: (2013)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Anakinra treatment for refractory cerebral autoinflammatory responses
por: Jang, Yoonhyuk, et al.
Publicado: (2022)

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
por: Faruqi, Aiman J., et al.
Publicado: (2022)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
por: Shalabi, Haneen, et al.
Publicado: (2020)

Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Bhat, Chandrika S., et al.
Publicado: (2021)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
por: Shalabi, Haneen, et al.
Publicado: (2015)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Anakinra/hydrocortisone/hydroxychloroquine: Toxic myopathy following drug toxicity: case report
Publicado: (2020)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Evusheld™ Pre-Exposure COVID-19 Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant (HSCT) and Cellular Therapy Recipients: A Single Institution Retrospective Series
por: DePriest, Brittany Paige, et al.
Publicado: (2023)

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra
por: Angeletti, Andrea, et al.
Publicado: (2021)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra
por: Gambacorta, Alessandro, et al.
Publicado: (2020)

Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities
por: Rocco, Joseph M., et al.
Publicado: (2023)

Anakinra: Various toxicities following off label use: 7 case reports
Publicado: (2021)

Sars-Cov-2 Infections in CAR T Cell Recipients
por: McNerney, Kevin O., et al.
Publicado: (2021)

Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Stredny, Coral M., et al.
Publicado: (2020)

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
por: Hsieh, Emily M., et al.
Publicado: (2022)

Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review
por: Ortiz-Sanjuán, Francisco, et al.
Publicado: (2015)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

Anakinra for patients with COVID-19
por: Maoujoud, Omar, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Valette, Xavier, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Effect of anakinra in COVID-19
por: Kooistra, Emma J, et al.
Publicado: (2020)

Anakinra: Jaundice: case report
Publicado: (2021)

Continuous IV infusion of anakinra
por: Saunders, Brittney N., et al.
Publicado: (2023)

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia
por: Zebley, Caitlin C., et al.
Publicado: (2021)

CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL
por: Epperly, Rebecca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_suruarvf14pu511klb4037g1kn